Boston Scientific to Acquire CryoVascular Systems
Boston Scientific has exercised its option to acquire CryoVascular Systems, a Los Gatos, Calif.-based company that manufactures an angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries.
CryoVascular Systems has developed a proprietary technology known as the PolarCath Peripheral Dilatation System, which utilizes liquid nitrous oxide to provide precise cooling of the diseased artery during balloon angioplasty -- a procedure known as CryoPlasty. The PolarCath system is designed to revascularize the artery and reduce the postprocedure rate of restenosis.
"The CryoPlasty procedure has become an important option for physicians whose patients are suffering from this disease, said Boston Scientific Chief Operating Officer Paul LaViolette." We have been impressed by the strong reception of the CryoPlasty procedure among physicians and look forward to continuing to offer this treatment option as part of our peripheral portfolio." Terms of the acquisition were not disclosed.